Sugi Predict

Sugi Predict / Compounds / SCHEMBL3870951

SCHEMBL3870951

SCHEMBL3870951

Nc1ccc(Cl)c(I)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 7/20 0.39
▸ CYP3A4 P08684 6/20 0.39
▸ TP53 P04637 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ THRB P10828 2/20 0.38
▸ RECQL P46063 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ APEX1 P27695 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ MCL1 Q07820 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ MAPK1 P28482 1/20 0.37
▸ CA12 O43570 2/20 0.36
▸ CA1 P00915 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2766622 0.79 TSHR (0.39) TSHRCYP3A4TP53ALDH1A1TDP1
SCHEMBL10873226 0.77 CYP3A4 (0.41) TSHRCYP3A4TP53TDP1MAPK1
SCHEMBL16249712 0.75 ALDH1A1 (0.37) TSHRCYP3A4TP53ALDH1A1TDP1
SCHEMBL3876173 0.75 TSHR (0.36) TSHRCYP3A4TP53ALDH1A1TDP1
SCHEMBL31636549 0.75 ALDH1A1 (0.48) TSHRCYP3A4TP53ALDH1A1TDP1
SCHEMBL29561813 0.75 ALDH1A1 (0.37) TSHRCYP3A4TP53ALDH1A1TDP1
SCHEMBL174757 0.75 CYP3A4 (0.46) TSHRCYP3A4TP53ALDH1A1TDP1
SCHEMBL526351 0.73 ALDH1A1 (0.50) TSHRCYP3A4TP53ALDH1A1TDP1
SCHEMBL331670 0.73 CYP2A6 (0.39) TSHRCYP3A4TP53ALDH1A1TDP1
Hydrochloric Acid SCHEMBL8714149 0.72 CYP3A4 (0.46) TSHRCYP3A4TP53ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 — — US disclosed
CN-114026073-B Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders ARRAY生物制药公司 2024-08-23 — — CN disclosed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 — — US disclosed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 — — US disclosed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 — — US disclosed
US-11634409-B2 Compounds for the treatment of BRAF-associated diseases and disorders ARRAY BIOPHARMA INC. (US) 2023-04-25 — — US disclosed
CN-115768750-A GCN2 modulator compounds 阿莱斯塔治疗公司 2023-03-07 — — CN disclosed
EP-4107146-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2022-12-28 — — EP disclosed
US-20220289721-A1 COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS ARRAY BIOPHARMA INC. (US) 2022-09-15 — — US disclosed
US-11414404-B2 Compounds for the treatment of BRAF-associated diseases and disorders ARRAY BIOPHARMA INC. (US) 2022-08-16 — — US disclosed
WO-2020261156-A1 QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS ARRAY BIOPHARMA INC. (US) 2020-12-30 — — WO disclosed
US-20140058129-A1 Phenylacetic Acid Derivatives NOVARTIS AG (CH) 2014-02-27 — — US disclosed
US-8586782-B2 Phenylacetic acid derivatives NOVARTIS AG (CH) 2013-11-19 — — US disclosed
US-8362294-B2 Phenylacetic acid derivatives NOVARTIS AG (CH) 2013-01-29 — — US disclosed
US-20130012585-A1 Phenylacetic Acid Derivatives MONOVICH LAUREN G (US) 2013-01-10 — — US disclosed
EP-2046723-B1 PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS NOVARTIS AG (CH) 2012-07-18 — — EP disclosed
US-20090209648-A1 Phenylacetic Acid Derivatives NOVARTIS AG (CH) 2009-08-20 — — US disclosed
CN-101479231-A Phenylacetic acid derivatives as COX-2 inhibitors NOVARTIS AG (CH) 2009-07-08 — — CN disclosed
EP-2046723-A2 PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS Novartis AG (CH) 2009-04-15 — — EP disclosed
WO-2008002853-A2 PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS NOVARTIS AG (CH) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 TSHR 1115/4885CYP3A4 3424/4885TP53 4741/4885
US-20140058129-A1 Phenylacetic Acid Derivatives PTGES2, PTGS2, GOT2 TSHR 2476/4885CYP3A4 86/4885TP53 2901/4885
US-11634409-B2 Compounds for the treatment of BRAF-associated diseases and disorders BRAF, NRAS, RAF1 TSHR 354/4885CYP3A4 1823/4885TP53 11/4885
US-11414404-B2 Compounds for the treatment of BRAF-associated diseases and disorders BRAF, NRAS, RAF1 TSHR 354/4885CYP3A4 1823/4885TP53 11/4885
US-20220289721-A1 COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS BRAF, NRAS, RAF1 TSHR 354/4885CYP3A4 1823/4885TP53 11/4885
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS EIF2AK4, GPR119, GCN1 TSHR 1868/4885CYP3A4 4035/4885TP53 4551/4885
US-20130012585-A1 Phenylacetic Acid Derivatives PTGES2, PTGS2, GOT2 TSHR 2476/4885CYP3A4 86/4885TP53 2901/4885
US-20090209648-A1 Phenylacetic Acid Derivatives PTGES2, PTGS2, PTGER2 TSHR 2586/4885CYP3A4 82/4885TP53 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.